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ABSTRACT
The coronavirus disease-2019 (COVID-19) pandemic has profoundly changed clinical care and research, including the
conduct of clinical trials, and the clinical research ecosystem will need to adapt to this transformed environment. The
Heart Failure Academic Research Consortium is a partnership between the Heart Failure Collaboratory and the Academic
Research Consortium, composed of academic investigators from the United States and Europe, patients, the U.S. Food
and Drug Administration, the National Institutes of Health, and industry members. A series of meetings were convened to
address the challenges caused by the COVID-19 pandemic, review options for maintaining or altering best practices, and
establish key recommendations for the conduct and analysis of clinical trials for cardiovascular disease and heart failure.
This paper summarizes the discussions and expert consensus recommendations. (J Am Coll Cardiol 2020;76:2368–78)
© 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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T

(COVID-19)

is preferred to noncollection to minimize

ABBREVIATIONS

pandemic has dramatically altered health

difﬁculties with interpretability and statisti-

AND ACRONYMS

he

coronavirus

disease-2019

care delivery and clinical research world-

cal assessment arising from missing data.

wide. Clinical trial activity apart from COVID-19

Case report forms may require speciﬁc ﬁelds

studies has plummeted. In April 2020, approximately

for COVID-19–focused elements to facilitate

90% of clinical trial sites closed to enrollment world-

understanding of the pandemic’s impact,

wide, with a 95% decline in cardiovascular trial activ-

including

ity (1,2). The rapid initiation of over 1,000 COVID-19

product delivery, follow-up completeness,

clinical trials contrasts with the decline in non–

safety assessments, event rates, and to assist

COVID-19 research.

clinical event committee adjudications (an

on

enrollment,

AE = adverse event
COVID-19 = coronavirus
disease-2019

FDA = Food and Drug

investigational

Administration

HF = heart failure
HF-ARC = Heart Failure
Collaboratory–Academic

In response to these issues, regulators, sponsors,

example can be found in the Supplemental

Research Consortium

and professional organizations including the U.S.

Appendix). Regional and country-speciﬁc

HFC = HF Collaboratory

Food and Drug Administration (FDA), National In-

COVID-19 infection rates may also aid inter-

NYHA = New York Heart

stitutes of Health (NIH), the European Medicines

pretation of study results. To assure integrity

Association

Agency, and the European Society of Cardiology have

of the clinical trial, permanent changes to

released guidance on the performance of clinical trials

study protocols, analysis plans, and informed

in the era of COVID-19 (3–6). These statements pro-

consents should be documented prospec-

mote the principles of safety for patients and research

tively, receive Institutional Review Board

team members while striving to preserve trial integ-

approval, and be communicated to patients

rity (7). Strategies to limit in-person data collection

(Central Illustration).

PGA = patient global
assessment

PRO = patient-reported
outcome

SAP = statistical analysis plans

and maintain physical distancing are suggested. In

Ideally these activities will accelerate use of inno-

response, trial telehealth and remote monitoring

vative methodologies and digital tools by the clinical

protocol amendments have surged (8). Nevertheless,

trial

although new regulatory and governmental guidance

studies and research sites will react variably to local

documents may facilitate remote and electronic

disease burdens, resources, and institutional capa-

data collection, speciﬁc methodologies and stan-

bilities (9). Additionally, although these suggestions

dardized practices have not been established (6,7).

aim to reinvigorate clinical research during and

The HF Collaboratory (HFC) is a multistakeholder

ecosystem,

following

the

acknowledging

current

that

pandemic,

individual

lasting

trans-

organization that seeks to improve evidence genera-

formation and global stakeholder cooperation will be

tion for new therapies, implementation of safe and

needed to prepare for future events, including pro-

effective treatments, and clinical trial efﬁciency;

tocols for virtual screening, electronic consenting,

HFC

in-

central institutional review boards, remote enroll-

vestigators, the FDA, NIH, industry, and payers (9).

ment, randomization, follow-up visits, site moni-

The Heart Failure Academic Research Consortium

toring,

(HF-ARC) working group was convened through a

collection, as well as statistical analysis plans to

partnership between the HFC and ARC, with repre-

handle mid-trial changes.

includes

patients,

clinicians,

clinical

endpoint

ascertainment,

and

sample

sentatives from the United States and Europe, to
develop a scientiﬁc expert statement of standardized

DATA AND TRIAL INTEGRITY

methods for heart failure (HF) clinical trials in
Typically, contract research organizations, sponsors,

response to the COVID-19 pandemic.

and study staff engage in frequent queries of site data

GENERAL PRINCIPLES

to help prevent missingness, retain patients, and
identify protocol deviations. However, sponsors and

The
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methods

described

in

for
the

adjudicating

consensus

Supplemental

are

Appendix,

contract research organizations have increasingly
implemented

remote

monitoring

during

the

Supplemental Figure 1, and Supplemental Table 1.

pandemic to collect data and ensure integrity with

These

adherence to Good Clinical Practice guidelines (10).

recommendations

focus

largely

on

data

collection and analysis (3–5,7). Sponsors and regula-

Typically,

tors must together decide which protocol procedures

trained research staff encourages patients to adhere

can be safely and accurately completed and which

to trial protocols, but remote pill counts may monitor

data are critical, and seek to maximize evidence

medication adherence and improve accountability at

acquisition while embracing ﬂexibility, including

lower cost than in-person visits (11). The stress and

protocol amendments and deviations when appro-

mental health sequelae of the pandemic may require

priate. When necessary, collection of imperfect data

increased

standardized

attention

to

direct

patient

counseling

well-being

from

and
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counseling by trial personnel to ensure completion of
protocolled activities. Central statistical monitoring
may provide an alternative method to in-person site
visits (12). This technique searches for sites or regions
with data inconsistencies and may better identify
sites for audit. The integrity and timely delivery of
investigational pharmaceutical products to patients
and investigators has been affected by the pandemic,
and

must

also

be

proactively

managed

by

sponsors and regulators.

ENDPOINT COLLECTION
Digital and remote methods of endpoint ascertainment have been suggested when possible (3–5,7).
Virtualization merits individual consideration for

HIGHLIGHTS
 The COVID-19 pandemic has profoundly
affected patient care and the conduct of
clinical trials.
 HF-ARC scientiﬁc expert panel developed
recommendations for the conduct and
analysis of heart failure trials during the
pandemic.
 The HF-ARC consensus recommendations
support ongoing clinical trials and
strengthen the clinical trial ecosystem,
which should have sustained beneﬁts in
the future.

each clinical trial, as the ability to acquire and analyze
these data depend on the patient population, inves-

from interviewer-based assessments can be pooled

tigational agent studied, and endpoints. Early and

with self-administered data. Thus, although imple-

direct communication with regulators is paramount to

mentation of remote PROs appears feasible, the

agree on changes to trial design or analysis. Although

preferred collection method will depend on speciﬁcs

endpoints collectable only in a clinical setting, such

of

as cardiopulmonary exercise testing, may have to be

ment (Table 1).

the

incorporating

study

and

PRO

instru-

modiﬁed or delayed, others may be collected by alter-

Few clinical trials independently assess dyspnea,

native or remote methods on time. Decision-making is

but it remains the most common multifactorial

inﬂuenced by trial characteristics and whether the

patient-reported symptom in HF (17). Dyspnea is

outcomes lie within the primary endpoints. As detailed

often measured using Likert or visual analog scales.

later in the text, alternative methods of assessment

The Likert is commonly assessed in paper format, but

often lack sufﬁcient evidence of reliability compared

may be done by telephone; the visual analog scale

with established methodologies. Studies under devel-

requires a visual reference either on paper or a digital

opment should investigate at baseline the within-

monitor. Although the psychometric properties of

patient agreement between in-clinic and remotely

these methods have not been carefully evaluated,

obtained measurements to prepare for unforeseen

interviewer and staff feedback are known to affect

future challenges to study execution.

patient responses, and selection of the appropriate

PATIENT-REPORTED OUTCOMES AND QUALITY-OF-LIFE

administration strategy is situationally dependent

ASSESSMENTS. Patient-reported outcome (PRO) in-

(Table 1).

struments

have

been

extensively

evaluated,

General health status PROs may be useful for pa-

including for remote administration (13). The HF-

tients with HF, separately or in combination with HF-

speciﬁc Kansas City Cardiomyopathy Questionnaire

speciﬁc instruments (16). PGA captures the global

(KCCQ) and Minnesota Living With Heart Failure

impact of disease and is one of the most widely used

Questionnaire (MLHFQ) are both designated Medical

PRO instruments in clinical trials (18). PGA does not

Device Development Tools by the FDA Center for

require baseline assessment as it incorporates com-

Devices and Radiological Health, and may be trans-

parison with a prior time point when asking whether

lated to digital or telephone formats from the original

and how the patient’s overall status has changed,

self-administered paper (14,15). Anchoring these

though patients may interpret baseline differently

PROs with patient global assessments (PGA) may

than investigators and recall may be imperfect. Like

assist with establishing thresholds for meaningful

dyspnea, PGA is commonly measured on a 7-point

change (16). Nevertheless, collection of these end-

Likert scale ranging from markedly better to mark-

points

the

edly worse, and can be assessed remotely and digi-

pandemic, compared to prior, may increase within-

tally (19). The Short Form-36 (SF-36) and EQ-5D

subject variability through environmental effects on

questionnaires are other general PRO instruments

patient responses, coaching by assessors and family

that have been used with paper collection, telephone

or

interview, and over the Internet. Among these, EQ-5D

using

caregivers,

remote

and

methodologies

heightened

during

susceptibility

to

missing data. It also remains unclear whether data

may be preferred to SF-36 due to greater validation.
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C ENTR AL I LL U STRA T I O N Management of Coronavirus Disease-2019 Impact on Non–Coronavirus Disease-2019
Clinical Trials

Psotka, M.A. et al. J Am Coll Cardiol. 2020;76(20):2368–78.

Coronavirus disease-2019 (COVID-19) has globally affected clinical trial performance, patient behavior, and clinical care. Most clinical trial sites ceased site-based
enrollments and procedures; adverse event reporting declined for enrolled patients. Patient mobility declined in response to governmental orders and fear of
infection, and patient-care changes include widespread reductions in cardiovascular hospitalizations and increased numbers of at-home cardiac arrests, which may be
due to COVID-19 or cardiovascular conditions. We evaluate methods to promote valid remote endpoint ascertainment, adjudication of COVID-19 and non–COVID-19
events, and suggest considerations for careful statistical analysis plan and protocol alterations that may be made in consultation with regulators.

COVID-19 may impair PRO interpretation. Infec-

 When a PRO is assessed, the mode of administra-

tion may worsen dyspnea and health-related qual-

tion should be recorded and similar scripts, in-

ity of life, perhaps persistently; social distancing

struments, and devices should be used before,

and home lockdown may limit patient activities

during, and after the pandemic, modifying only as

that provoke breathlessness. The economic impact

necessary to maximize data collection while

and concerns for infection may affect mental health

maintaining procedural integrity.

and quality of life. Accordingly, PRO data during

 PGA, EQ-5D, KCCQ, and MLHFQ are validated PROs

COVID-19 may require statistical adjustment for

well-suited for HF trials employing remote study

temporality and regionality, and contextualization

visits, including those performed during the

of the pandemic’s psychological burden, which may
be

concurrently

PROs.

captured

with

disease-agnostic

COVID-19 pandemic.
 COVID-19 could inﬂuence PRO responses in complex ways. Results should be interpreted in the

2371
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T A B L E 1 Advantages and Drawbacks of Remote Collection Strategies for PRO and Dyspnea Assessment

Strategy

Advantages

Drawbacks

Mail, paper











Mail, paper, with
telephone script

 Consistent with most trial operations
 Ensures completion
 Limited change to IRB/protocol/consent

 Potential inﬂuence from interviewer/observer
 Requires appointment

Telephone-based
interview, paper or
digital

 Limited change to IRB/protocol/consent
 Proven track record in trials
 Ability to reduce missing data

 Potential inﬂuence from interviewer
 Less validated than paper form
 Requires conﬁrmation that patient is the responder

Internet-based, digital

 Similarity to paper form
 Ability to reduce missing data and inability to skip
response items with streamlined data transfer
 Used in clinical practice
 Immediate feedback






Requires access to computer and Internet (biased)
Requires IRB/protocol/consent modiﬁcations
Cost required for site construction
Inability to control interference (bias or help) from
caregivers

Mobile phone-based,
digital

 Similarity to paper form
 Ability to reduce missing data and inability to skip
response items with streamlined data transfer
 Used in prior research
 Immediate feedback






Requires mobile phone service and data use (biased)
Requires IRB/protocol/consent modiﬁcations
Cost required for site construction
Inability to control interference (bias or help) from
caregivers

Consistent with validation
Consistent with most trial operations
Limited change to IRB/protocol/consent
Remains self-administered

Unobserved and nonproctored
Relatively higher cost and inefﬁciency
Inability to control missing data and response rate
Inability to control interference from caregivers

IRB ¼ institutional review board; PRO ¼ patient-reported outcomes.

context of regional timing and severity of the

capture these data may be differentially available in

pandemic,

COVID-19

the population. Finally, lifestyle changes with social

infection status, which may be assessed by sero-

distancing may substantially reduce overall physical

logical status.

activity and exertional tolerance, independent of

patient

symptoms,

and

disease-related changes.
FUNCTIONAL AND EXERCISE MEASURES. New York

Heart Association (NYHA) functional classiﬁcation is

 Some exertional and functional testing measures

widely used to assess functional status for patients

have digital remote options, but changes in

with HF (20). NYHA functional class can be collected

assessment method and variability associated with

remotely by patient interview but may be affected by

remote data collection may add statistical noise.

environmental factors similarly to PROs. Objective

 To facilitate analysis, it is best to record the mode

measurement of maximal or submaximal exercise

of test administration, modifying only as necessary

capacity requires equipment, and trials with short-

to maximize data collection while maintaining

term hemodynamic or functional endpoints may be

procedural integrity.

temporarily suspended then restarted when the

 NYHA functional class may be remotely assessed

pandemic is better controlled. Although cardiopul-

but the means of collection should be recorded and

monary exercise testing and peak V O2 measurement

its value to clinical trials should continue to be re-

may not be possible remotely, there are established

examined.

strategies to collect accelerometer-based activity for
timed walking tests such as the 6-min walk test (21).

IMAGING. Although remote use of many cardiac im-

Validation studies have been published for 2 home

aging modalities is infeasible, the growth of minia-

6-min walk test smartphone applications, however,

turized and portable echocardiographic platforms

the remote capture of these data elements has limi-

could lessen the technological barriers to image

tations due to measurement error, sometimes poor

acquisition (26). Nonetheless, echocardiography has

device reliability, lack of performance testing, and

been validated only with trained users, and patient-

frequent missing data (21–24). In addition, patients

acquired images are anticipated to be of variable

may need reminders to wear nonimplantable devices

quality with missing data points. Although technician

to record their activity, the technology may have

home visits may be the option of highest quality, and

psychological consequences that alter behavior, it is

greatest expenditures, because of suboptimal posi-

unclear whether data from different modalities can be

tioning and privacy concerns, they face data collec-

pooled, and mask-wearing may affect performance

tion

(25). Activity data from implantable devices may also

acquisition may be best delayed until it can be safely

be used, but many of the technologies required to

performed in the health care setting.

and

accuracy

limitations.

Thus,

image
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T A B L E 2 Competing Inﬂuences of COVID-19 on CV Event Rates

Type of Event
Effects on Events

Reduction in event rates

Nonfatal CV Events

Fatal CV Events

 Fear of hospitalization and contracting COVID-19 in
the inpatient setting (Y CV and HF hospitalizations,
Y myocardial infarctions)
 Hospitalization attributed to COVID-19 (Y CV and HF
hospitalizations, even with concurrent exacerbation)
 Decreased patient physical activity and provoked
symptoms (Y clinical visits and hospitalizations)

 Fear of hospitalization, reducing adjudication (Y CV and
HF deaths)
 Sicker patients may reside in skilled nursing facilities
with exposure to COVID-19 ([ COVID-19 deaths with
Y CV and HF deaths)
 Financial incentive to attribute death to COVID-19 in the
United States (Y CV and HF deaths)

 Potential increased adherence to CV therapies
(Y CV and HF fatal and nonfatal events)
Increase in event rates

 COVID-19 infection & inﬂammation increases risk of
 Delayed presentations to medical care ([ deaths)
underlying HF exacerbation ([ CV and HF events
including [ myocardial infarctions)
 Increased thrombosis associated with COVID-19
([ CV events)
 COVID-19 increases risk of renal injury ([ renal injury)
 Concern that cardiovascular medications such as angiotensin system antagonists may increase risk for or worsen COVID-19
([ CV and HF events and [ CV and HF deaths)
 Inability to obtain therapies, including due to cost (due to loss of employment) or fear of contracting COVID-19 ([ CV events,
[ outpatient worsening HF events, [ CV and HF deaths)

Unclear effect on event rates

 Overlapping biomarker or clinical proﬁles of HF and CV diseases with COVID-19 (Y or [ CV and HF events including
myocardial infarctions)

Increased missing events or
events of unknown cause

 Increased comingled events at home without documentation or reporting
 Decline or reassignment of study personnel with decreased source documentation and data collection
 Undiagnosed COVID-19

COPD ¼ chronic obstructive pulmonary disease; COVID-19 ¼ coronavirus disease-2019; CV ¼ cardiovascular; HF ¼ heart failure.

 Multiple portable ultrasound-based data acquisi-

 Home-based

biomarker

and

serum

chemistry

tion platforms are in use for clinical purposes;

testing may be leveraged as an option for patients

however, remote echocardiographic assessment is

without obvious COVID-19; technical and inter-

only validated with trained users.

pretation challenges for biomarkers remain, and

 Technician home visits may be possible for small

shared risk assessment and decision-making with

studies, but require training and quality control by

patients should determine which methodology for

a centralized core laboratory to ensure data

safety laboratory assessment, if any, can be

reliability.
BIOMARKERS. Biomarkers including troponin and

natriuretic peptides are commonly used for clinical
trial inclusion criteria, endpoints, event adjudication,

achieved.
 Biosample collection for all clinical trial enrollees
may assist with adjudication and interpretation of
COVID-19–associated events.

safety, and mechanistic evaluation or monitoring (27).

HOSPITALIZATION AND MORTALITY ENDPOINTS.

COVID-19 complicates biomarker use because infec-

Assessment of traditional clinical trial outcomes,

tion is associated with increased circulating levels,

including emergency department visits, hospitaliza-

and they are risk markers for severe COVID-19 disease

tions, and mortality, may be confounded by signs,

and worse outcomes (28,29). Although in many cases,

symptoms, and biomarkers of COVID-19 that overlap

biomarker changes appear to be due to noncardiac

with HF, increased overall death rates due to

critical illness, the COVID-19 coronavirus appears to

COVID-19, direct myocardial injury with COVID-19,

have tropism for the myocardium and vasculature

and altered patient and clinician behavior from soci-

(30). Thus, COVID-19 complicates adjudication of

etal changes and governmental recommendations

myocardial injury events and worsening HF events,

(28,30). Patients with cardiovascular comorbidities

because the symptomatology and biomarkers may be

and HF appear to be at greater risk of more severe

consistent with either COVID-19 or primary cardio-

COVID-19 disease in addition to an increased risk of

vascular conditions (27,31). Additionally, biomarker

cardiovascular adverse events (32). Although overall

measurement and serum chemistries may not be

COVID-19 hospitalization and mortality rates remain

feasible due to site closures. Once accurate antibody

low and vary by geographic location, COVID-19

assays become available, stored biorepositories can

could contribute to the outcome in any individual

provide a more complete evaluation of known and

case,

unknown COVID-19 infections in trial populations.

data interpretation.

complicating

event

adjudication

and
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Patient
response

behavior
to

fears

has
of

changed

infection

in

 Changes in cardiovascular event rates in response

social

to COVID-19, and the adjudication and analysis of

markedly
and

to

distancing measures enacted by local authorities,

these events, will be complex (Table 2).

leading to decreased medical care and altered

 For nonfatal and fatal events, information on

nonfatal event rates. In Italy and the United States,

COVID-19 status at the time aids in adjudication

the COVID-19 pandemic was temporally associated

and analysis: speciﬁcally, whether the patient was

with a 40% decrease in presentation for acute cor-

deﬁnitely positive for COVID-19, deﬁnitely nega-

onary syndromes (33,34). Worldwide, HF hospitali-

tive, unknown but suspected positive, or unknown

zation rates have dropped up to 50% with regional

and suspected negative.

COVID-19 spread and governmental activity re-

 Prospective and retrospective collection of COVID-19

strictions (35) (Supplemental References). Patients

symptoms, infection status, and events, which may

may forego care to avoid contact with the medical

include nucleic acid and serological testing, should

system. Alternatively, diminished rates of myocar-

be performed to aid analysis and interpretation of

dial infarction and HF hospitalization may be due to

the data (see case report form in the Supplemental

misdiagnosis, fewer true events associated with
increased sedentary behavior, or outpatient treat-

Appendix).
 Clinical events committees

should adjudicate

ment of worsening HF. The consequences of the

whether COVID-19 was uninvolved, contributory,

complex interplay of individual and societal factors

or the primary cause of cardiovascular and non-

on cardiovascular health and event rates remain

cardiovascular events.

unclear in some cases (Table 2). Nevertheless,
follow-up

ADVERSE EVENTS. Behavioral and societal forces

required to demonstrate efﬁcacy, and given difﬁ-

decreasing are also likely to limit ascertainment of

culties ascertaining cause of death, hamper inter-

adverse events (AEs). Typically, AEs are collected by

pretation of clinical trial results if fatal event rates

clinical chart review and patient report; thus,

increase.

decreased contact and chart review by monitors can

decreased

events

may

lengthen

the

The effect of COVID-19 on patient behavior may

reduce ascertainment. Telephone or virtual visits that

also lead to altered rates and misclassiﬁcation of

include AE checklists may capture some of this in-

fatal events. In Lombardy, Italy, during the ﬁrst

formation, but rely on access and may be more difﬁ-

40 days of the outbreak, there was an almost 60%

cult for older and sicker patients (37). Traditional mail

increase in out-of-hospital cardiac arrests compared

may be more accessible but at greater cost and subject

with the same time period the previous year (36).

to increased risk of missing data.

These deaths rose contemporaneously with regional

Nevertheless, there is general consensus that clin-

infections, but of the excess, only 75% were sus-

ical trials collect excessive AE information and the

pected or diagnosed with COVID-19, suggesting a

pandemic presents an opportunity to reduce that

potential concomitant increase in non–COVID-19

burden in consultation with regulators (38). The FDA

mortality, possibly from avoidance of appropriate

has suggested collecting more extensive AE data on a

medical care. However, deaths due to COVID-19 or

limited sample of enrolled patients, or a more focused

other noncardiovascular etiologies are unlikely to be

symptom catalog on all subjects, to reduce the

treatable with investigational HF therapies and may

recording of AEs unlikely to contribute new knowl-

dilute a treatment effect. In addition, with limited

edge about the risks of the intervention (38).

data and documentation available for adjudication,

 Patient reporting of AEs can be accomplished

clinical events committees may be unable to determine the cause of death. This may be particularly
pertinent to out-of-hospital sudden death or events
of unknown etiology, which are frequently ascribed
to cardiovascular causes, but may be best prespeciﬁed as noncardiovascular or analyzed as part
of sensitivity analyses. Local COVID-19 infection
prevalence and mortality patterns may be needed to
allow proper adjudication of events, acknowledging

remotely by virtual visit or telephone and may be
streamlined with questionnaires or focused event
checklists.
 In consultation with regulators, selective safety
data collection may be acceptable when the intervention’s safety proﬁle is well-characterized, for
instance, on a subset of the enrolled population.

SOCIOECONOMIC DISPARITIES

that patient deaths are often due to a combination
of concurrent illnesses, and that consistency in

Ample evidence shows that socioeconomic factors

adjudication

affect the risk of exposure, transmission, and devel-

accuracy.

is

more

crucial

than

complete

opment

of

severe

COVID-19,

with

patients

of
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F I G U R E 1 Trial Timeline Statistical Assessment

Still in
design
phase

In
screening

Fewer than
20% of
endpoints
collected

20%-80% of
endpoints
collected

More than
80% of
endpoints
collected

Last patient
last visit
completed

The progression of a clinical trial from design to completion, color coded by proximity to database lock and analysis (dark green ¼ ready for
analysis; dark red ¼ inappropriate for analysis). This concept can help assess initiation and stopping decisions. For instance, given difﬁculties
with recruitment and enrollment, trials with fewer than approximately 20% of endpoints collected in the dark red period may consider
pausing initiation or recruitment in consultation with regulators, until COVID-19 has waned. Alternatively, trials with >80% of endpoints
collected in green, may recalculate their power and consider stopping the trial to avoid the consequences of COVID-19 on endpoint
ascertainment, adjudication, and statistical analysis plan (SAP) adjustment; with at least 80% of events collected, there may be only a
modest 10% decrement in statistical power. Trials with approximately 20% to 80% of endpoints collected need to consider how best to adapt
to the issues covered in this paper, including remote endpoint collection, methods to minimize missing data, and SAP modiﬁcations.

traditionally

experi-

outcomes may also merit consideration of prospec-

encing higher rates of disease exposure, contraction,

disadvantaged

backgrounds

tively identiﬁed sensitivity analyses among socio-

and critical illness. In New York, areas of the city with

economic and demographic groups to understand the

greater poverty and composed of more ethnic and

impact on overall treatment effect within a clinical

racial minorities had increased rates of hospitaliza-

trial.

tion and death from COVID-19 than wealthier and
more homogenous regions after adjustment for pop-

STATISTICAL CONSIDERATIONS

ulation density (39). Furthermore, racial and ethnic
minorities had disproportionately increased rates of

COVID-19 challenges the design, execution, and

death (40). In China, Italy, and the United States, the

analysis of clinical trials. Although statistical analysis

pandemic has particularly affected older patients,

plans (SAP) were written following extensive negoti-

with more hospitalizations and higher rates of critical

ations between statisticians, sponsors, investigators,

illness and mortality (41). In the Campania region of

and regulators, the pandemic may require prospec-

Italy, the drop in presentation of patients for acute

tive SAP alterations to allow the collected data to best

coronary syndromes was greater for elderly than for

answer the clinical questions under study. SAP revi-

younger patients, and more pronounced for women

sion is complicated and consequential, and should be

than men (33). These disparities must be considered

done and documented prospectively in concert with

in the context of clinical trial execution, because

regulators to help ensure integrity of the study and

COVID-19 exacerbates longstanding inequalities in

analysis. Although sponsors, regulators, and in-

clinical trial participation for women, the elderly, and

vestigators recognize that trials in early stages of

minority populations; additional sponsor resources

implementation face the greatest potential adverse

may be needed to manage these differences (9). On

impact of the pandemic, appropriate adaptation and

one hand, remote patient assessment may improve

targeted ﬂexibility could allow these trials to succeed.

inclusion of under-represented populations, particu-

Statistical considerations may inﬂuence what data to

larly those in rural areas with transportation or access

collect, given variable susceptibility to statistically

barriers. However, for those without telephone,

informative missing data and bias, and statistical

Internet, or mailing addresses, the disparity may

adjustment may allow data collected by altered

hamper participation. The differential effect on

methods to be used. Furthermore, projection of
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statistical power on the basis of the number of

these rely on distinct statistical assumptions that

collected events, alterations in event rates, and

are best prospectively identiﬁed and justiﬁed in

enrollee counts may inform sponsor and scientiﬁc

the SAP. The reasons data are missing cannot be

decisions surrounding initiating or pausing enroll-

veriﬁed from the nonmissing data, thus distinct

ment, as well as potentially stopping the clinical trial

approaches should be used as sensitivity analyses

earlier than originally intended. We recommend

to conﬁrm treatment effects are unaltered by

considering the following issues:

different

missingness

postulations.

No

single

solution will apply to all studies affected by
 For

decision

COVID-19. Stakeholders including regulators will

regarding data censoring in response to the

a

time-to-event

endpoint,

the

likely use multiple coordinated assessments to

pandemic needs to balance loss of statistical power

understand the data, and noninferiority trials may

with confounding of inference caused by including

be more challenging than superiority trials to

pandemic-affected data. For a trial that has

evaluate in the presence of missing data.

collected approximately 80% of its endpoints

 Studies under development should prepare for

before COVID-19, there may only be a small

unexpected catastrophic events similar to this

decrement in statistical power, and censoring may

pandemic by outlining in their SAP how to handle

be favored; sponsors may consider stopping the

such natural disasters.

trial immediately and analyzing the data to avoid
the analytic and statistical complications of the

CONCLUSIONS

pandemic (Figure 1). Alternatively, creation of a
modiﬁed composite endpoint including only reli-

The COVID-19 pandemic has profoundly changed

ably ascertained components may be used.

clinical care and research including the performance

 If approximately 20% to 80% of endpoints have

and analysis of clinical trials. We have summarized

been collected, endpoints may either need to be

expert consensus recommendations for clinical trials;

modiﬁed or stratiﬁed on the basis of patient-

these principles should also be incorporated into

speciﬁc impact of the COVID-19 pandemic and the

contingency planning for future public health crises

feasibility of endpoint ascertainment. A new SAP

and systemic disruptions, including potential resur-

would speciﬁcally describe the analytic approach

gence of COVID-19, to allow more seamless continu-

for data missing because of COVID-19, which may

ation of clinical research. Although some clinical

affect the primary outcome analysis or subsequent

research programs may unfortunately be substan-

sensitivity analyses.

tially adversely affected by COVID-19, we hope our

 For a trial that has enrolled few patients or for

suggestions will help salvage ongoing clinical inves-

which few endpoints have been collected, sponsors

tigation and strengthen the clinical trial environment

may consider either substantially revising the SAP,

for the future.

or designing a new trial to begin after the COVID-19
pandemic has sufﬁciently waned, to account for
changes to the clinical trial ecosystem.
 Statistically accounting for the timeline and in-
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